Health Guard recently announced the successful closing of its Pre-IPO financing, raising RMB 1.015 billion, with major investors including CCB International, Yunfeng Capital, Jemincare, and Yingke PE,.

CEC Capital Group and WinX Capital served as the financial advisors for Health Guard in this transaction.

The proceeds from this round of financing will be primarily used for clinical research of Health Guard's recombinant human papillomavirus (HPV) trivalent (16/18/58 type) vaccine and recombinant human papillomavirus (HPV) nonvalent (6/11/16/18/31/33/45/52/58 type) vaccines. It will also be utilized for the construction of a vaccine production base in Kunming, pre-clinical and clinical research of recombinant norovirus vaccines, pre-clinical and clinical research of recombinant COVID-19 vaccines, and pre-clinical research of other pipeline products, as well as for additional working capital.